PMID- 23207765
OWN - NLM
STAT- MEDLINE
DCOM- 20130521
LR  - 20190720
IS  - 1347-5215 (Electronic)
IS  - 0918-6158 (Linking)
VI  - 35
IP  - 12
DP  - 2012
TI  - Exposure to multiwalled carbon nanotubes and allergen promotes early- and 
      late-phase increases in airway resistance in mice.
PG  - 2133-40
AB  - The facilitating effects of multiwalled carbon nanotubes (MWCNT) on allergic 
      asthma have not been sufficiently examined, although MWCNT appear to 
      significantly increase the risk of health problems from occupational or 
      environmental exposure. In this study, we examined whether sensitization by the 
      combination of MWCNT with ovalbumin (OVA) promotes allergic asthmatic responses. 
      BALB/c mice administered vehicle, MWCNT, OVA, or MWCNT+OVA through an intranasal 
      route were challenged with OVA intratracheally four times. In the MWCNT+OVA 
      group, the fourth challenge caused not only early- but also late-phase increases 
      in airway resistance, although these responses were not observed in the vehicle, 
      MWCNT, or OVA group; furthermore, the extents of the early and late responses 
      were comparable to those in mice systemically sensitized with OVA+alum. 
      Sensitization with MWCNT and OVA promoted airway inflammation and goblet cell 
      hyperplasia in the lung compared with the vehicle, MWCNT or OVA group. In 
      addition, adjuvant activity for OVA-specific immunoglobulin E (IgE), IgG1, and 
      IgG2a production in serum and increased levels of interleukin-4 (IL-4), IL-5, 
      IL-13, and IL-17 in the lung tissue were observed. In conclusion, these results 
      suggest that exposure to MWCNT and antigen can induce a biphasic increase in 
      airway resistance, airway inflammation, goblet cell hyperplasia, and the 
      production of antigen-specific antibodies. This study highlights the risk of 
      exposure to a combination of MWCNT with antigen.
FAU - Mizutani, Nobuaki
AU  - Mizutani N
AD  - Department of Pharmacology, Kobe Pharmaceutical University, 4-19-1 Motoyamakita, 
      Higashinada, Kobe 658-8558, Japan. mizutani@kobepharma-u.ac.jp
FAU - Nabe, Takeshi
AU  - Nabe T
FAU - Yoshino, Shin
AU  - Yoshino S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Allergens)
RN  - 0 (Alum Compounds)
RN  - 0 (Immunoglobulins)
RN  - 0 (Interleukins)
RN  - 0 (Nanotubes, Carbon)
RN  - 0 (ovalbumin-alum)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Airway Resistance/*drug effects/immunology
MH  - Allergens/*adverse effects/immunology
MH  - Alum Compounds
MH  - Animals
MH  - Asthma/*chemically induced/immunology/metabolism/pathology
MH  - Goblet Cells/drug effects/pathology
MH  - Hyperplasia
MH  - Hypersensitivity/*immunology/metabolism/pathology
MH  - Immunoglobulins/blood
MH  - Inflammation/*chemically induced/immunology
MH  - Interleukins/metabolism
MH  - Lung/*drug effects/immunology/metabolism/pathology
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Nanotubes, Carbon/*adverse effects
MH  - Ovalbumin/immunology
EDAT- 2012/12/05 06:00
MHDA- 2013/05/23 06:00
CRDT- 2012/12/05 06:00
PHST- 2012/12/05 06:00 [entrez]
PHST- 2012/12/05 06:00 [pubmed]
PHST- 2013/05/23 06:00 [medline]
AID - DN/JST.JSTAGE/bpb/b12-00357 [pii]
AID - 10.1248/bpb.b12-00357 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2012;35(12):2133-40. doi: 10.1248/bpb.b12-00357.